Compare AbbVie Inc (ABBV) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Avantis US Small Cap Value ETF — how do they compare? AbbVie Inc trades at $249.8 (market cap $441.94B), while Avantis US Small Cap Value ETF trades at $126.75. The key difference: AbbVie Inc pays a 2.77% dividend while Avantis US Small Cap Value ETF pays none, and Avantis US Small Cap Value ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | AVUV | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $128.74 |
52-Week Low | $197.38 | $93.93 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
AVUV trades at $127.03, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend with moving averages strongly supporting upside momentum while oscillators remain neutral. The ETF has attracted significant attention for its small-cap value exposure, with recent articles highlighting its strong performance relative to broader small-cap indices and its role in diversifying tech-heavy portfolios.
Outlook remains positive as small-cap value continues outperforming growth stocks in 2026. Investment opportunity lies in continued rate cut expectations and regional bank exposure driving returns. Key risks include sensitivity to interest rate changes, higher volatility typical of small-caps, and concentrated US market exposure limiting global diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
